Learning outcomes
By the end of this lesson you should be able to: explain what an enzyme does and what it does not change; draw the Michaelis-Menten curve and explain the meaning of Vmax and of Km; state the factors that affect reaction rate and distinguish competitive from non-competitive inhibition; recognise the shape of a Lineweaver-Burk plot and say what it is used for; and apply Km as an inverse measure of affinity in a clinical or experimental context.
Prerequisites
Lesson 3 (Protein structure hierarchy). You need the idea that a protein's folded shape creates a specific binding site.
The big idea
The two properties in that definition come as a pair and are conventionally examined together. An enzyme does not make an unfavourable reaction favourable: it only gets there faster, and the final equilibrium is the same as it would be without it. And it is not consumed: each enzyme molecule can process its substrate millions of times over, which is why the concentrations that matter inside a cell are micromolar rather than molar.
How catalysis works
An enzyme has an active site — a pocket on its surface lined by specific side chains — that binds a substrate, holds it in a precise orientation, and participates directly in the chemical step, often by donating or accepting a proton or by stabilising a charged intermediate. Two pictures of binding have been used historically: lock and key, in which the site is perfectly pre-formed, and induced fit, in which binding itself changes the shape of the protein so that catalysis can only occur in the bound state. Induced fit is the current understanding, and it explains why enzymes discriminate so sharply between chemically similar substrates.
| Property | Effect on rate | Why |
|---|---|---|
| Enzyme concentration | Proportional — doubling the enzyme doubles Vmax | More catalytic sites are available; the enzyme is not consumed |
| Substrate concentration | First-order then zero-order — the curve plateaus at Vmax | At low substrate the sites are mostly empty; at saturation, all sites are occupied |
| Temperature | Rises to an optimum, then falls steeply | Kinetic energy helps until the protein begins to denature |
| pH | Rises to an optimum, then falls | The state of the ionisable side chains at the active site changes |
| Inhibitors | Reduce the rate, by mechanisms described below | They either compete for the site or act elsewhere on the molecule |
Worked example: Michaelis-Menten kinetics
The relationship between substrate concentration and rate is a rectangular hyperbola. At low substrate, doubling the substrate roughly doubles the rate. As substrate rises, the slope flattens, and above a certain point the rate stops responding to substrate entirely. That plateau is Vmax, and the substrate concentration at which the rate is exactly half of Vmax is Km — the Michaelis constant.
| Quantity | Meaning | What changes it |
|---|---|---|
| Vmax | The maximum rate, when every active site is occupied at all times | Only the enzyme concentration: Vmax = kcat x [E]. Adding substrate cannot exceed it |
| Km | The substrate concentration at which the rate is half of Vmax, and therefore a measure of affinity: small Km, high affinity | A change in the enzyme itself — a mutation in the active site, or a competitive inhibitor |
| kcat (turnover number) | How many substrate molecules one enzyme converts per second when saturated | The chemical step at the active site; can be slowed by a mutation at the catalytic residue |
| kcat / Km | The specificity constant, which allows comparison of two substrates for the same enzyme | Anything that affects either constant |
The plateau has a molecular explanation that is worth stating explicitly, because it is the question most often asked in an oral examination. At saturation, every enzyme molecule has a substrate bound at every moment. Adding more substrate cannot create more enzyme. The rate therefore depends only on how fast each molecule can convert what it holds and release the products — so Vmax = kcat x [E], which is why increasing enzyme concentration is the only way to raise a saturated rate.
Inhibition
| Type | Mechanism | Effect on Km | Effect on Vmax | Classic example |
|---|---|---|---|---|
| Competitive | The inhibitor binds the active site, competing with the substrate | Increases (less apparent affinity) | Unchanged — a high enough substrate concentration can out-compete it | Malonate against succinate dehydrogenase; statins against HMG-CoA reductase; methotrexate against dihydrofolate reductase |
| Non-competitive | The inhibitor binds elsewhere, changing the shape of the enzyme | Unchanged | Reduced — adding substrate cannot restore the rate | Heavy-metal ions binding cysteines; allosteric inhibitors |
| Uncompetitive | The inhibitor binds only the enzyme-substrate complex | Reduced | Reduced | Rare in practice, but part of the standard curriculum |
For a competitive inhibitor, the key clinical observation is that the inhibition can be overcome by raising the substrate concentration, because the two are competing for the same site. That is exactly why methotrexate — a structural analogue of the folic acid precursor dihydrofolate — is given in high doses to shut down DNA synthesis in leukaemia, and why leucovorin (folinic acid) is used to rescue the healthy cells by supplying a bypass.
Clinical correlation: enzymes in diagnosis
Blood is a convenient place to look for intracellular enzymes, because when a tissue is damaged its cells leak. A serum enzyme level is therefore a measure of how much of that tissue is dying, and of how recently. The interpretation relies on two properties: which tissue contains the enzyme in quantity, and how fast it is cleared from plasma.
| Enzyme | Principal source | Timing after myocardial infarction | Note |
|---|---|---|---|
| Troponin I and T | Cardiac muscle | Rises within about 3 to 6 hours, peaks at about 24 hours, and remains elevated for days | Cardiac-specific, and the test of choice |
| Creatine kinase MB (CK-MB) | Cardiac muscle, with a small contribution from skeletal muscle | Rises within about 3 to 6 hours and returns to baseline within about 48 to 72 hours | Used to detect re-infarction, because it clears fast enough to rise again |
| Aspartate aminotransferase (AST) | Liver, heart, skeletal muscle, red cells | Rises within 6 to 8 hours, peaks at 24 to 48 hours | Not liver-specific; also rises in muscle injury and haemolysis |
| Alanine aminotransferase (ALT) | Liver | Rises and falls over days | More liver-specific than AST |
| Alkaline phosphatase | Bile canaliculi, bone, placenta | Rises over days | Raised in bile duct obstruction and in bone disease; distinguishes with a gamma-glutamyl transferase |
An enzyme-catalysed reaction is running at Vmax. What is happening at the molecular level?
Common mistakes
Watch outSaying an enzyme changes the equilibrium position in favour of products. It accelerates both forward and reverse reactions; the ratio at equilibrium is the same as it would be uncatalysed. Enzymes are rate accelerators, not equilibrium movers.
Watch outTreating Km as a substrate concentration that is 'optimal'. It is the concentration at half-maximal rate, not the best concentration. It is an inverse measure of affinity, not a threshold.
Watch outSaying a competitive inhibitor lowers Vmax. It does not — at high enough substrate concentration the substrate wins and Vmax is restored. A lowered Vmax with unchanged Km is non-competitive inhibition.
Check your understanding
What is the difference between Vmax and Km?
Why can adding substrate overcome the effect of a competitive inhibitor but not of a non-competitive one?
Why is CK-MB useful for detecting a second myocardial infarction after the first?
Multiple choice
Which statement about Vmax is correct?
A drug lowers the Km of an enzyme for its substrate and slightly reduces Vmax. Which is the most likely mechanism?
Which of the following correctly distinguishes competitive from non-competitive inhibition?
An enzyme-catalysed reaction is running at Vmax. What is happening at the molecular level?
Which statement about enzymes is correct?
Summary and next
Enzymes are protein catalysts: they lower the activation energy without being consumed and without moving the equilibrium. Their kinetics are described by Michaelis-Menten: a rate that rises with substrate and plateaus at Vmax, which is proportional to enzyme concentration, with Km — the substrate concentration at half-maximal rate — as an inverse measure of affinity. Competitive inhibitors raise Km without lowering Vmax, because substrate can out-compete them; non-competitive inhibitors lower Vmax without changing Km. Because damaged cells leak intracellular enzymes, serum enzyme measurements report the site, the size and the timing of tissue injury.
Next: module two, where carbohydrates, lipids and membranes take the chemistry into the fuel and the barrier — and where the same structural principles, applied to membranes rather than proteins, become the biochemist's main subject.